Haemonetics (HAE) Liabilities and Shareholders Equity (2010 - 2026)

Haemonetics has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $2.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 2.24% year-over-year to $2.4 billion; the trailing twelve-month figure through Mar 2026 stood at $9.8 billion (down 2.56% YoY), and the FY2026 full-year result was $2.4 billion, down 2.24% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $2.4 billion, down from $2.5 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $2.5 billion in Q2 2024, with the low at $1.8 billion in Q3 2022.
• Average Liabilities and Shareholders Equity over 5 years is $2.2 billion, with a median of $2.2 billion recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity surged 38.94% in 2022 and slipped 3.29% in 2025.
• Tracing HAE's Liabilities and Shareholders Equity over 5 years: stood at $1.9 billion in 2022, then rose by 17.16% to $2.2 billion in 2023, then grew by 15.04% to $2.5 billion in 2024, then slipped by 1.6% to $2.5 billion in 2025, then declined by 3.81% to $2.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.4 billion (Q1 2026), $2.5 billion (Q4 2025), and $2.4 billion (Q3 2025), per Business Quant data.

Peer Comparison